Therapy for fungal diseases: Opportunities and priorities

David W. Denning; William W. Hope

doi:10.1016/j.tim.2010.02.004

Therapy for fungal diseases: Opportunities and priorities

David W. Denning, William W. Hope

Research output: Contribution to journal › Article › peer-review

1386 Downloads (Pure)

Abstract

This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed. © 2010 Elsevier Ltd.

Original language	English
Pages (from-to)	195-204
Number of pages	9
Journal	Trends in Microbiology
Volume	18
Issue number	5
DOIs	https://doi.org/10.1016/j.tim.2010.02.004
Publication status	Published - May 2010

Access to Document

10.1016/j.tim.2010.02.004

POST-PEER-REVIEW-PUBLISHERS.PDFFinal published version, 445 KB

Cite this

@article{ba77e8d4c6d54376bf9345aaa3003fb8,

title = "Therapy for fungal diseases: Opportunities and priorities",

abstract = "This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed. {\textcopyright} 2010 Elsevier Ltd.",

author = "Denning, {David W.} and Hope, {William W.}",

year = "2010",

month = may,

doi = "10.1016/j.tim.2010.02.004",

language = "English",

volume = "18",

pages = "195--204",

journal = "Trends in Microbiology",

issn = "1878-4380",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - Therapy for fungal diseases: Opportunities and priorities

AU - Denning, David W.

AU - Hope, William W.

PY - 2010/5

Y1 - 2010/5

N2 - This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed. © 2010 Elsevier Ltd.

AB - This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed. © 2010 Elsevier Ltd.

U2 - 10.1016/j.tim.2010.02.004

DO - 10.1016/j.tim.2010.02.004

M3 - Article

SN - 1878-4380

VL - 18

SP - 195

EP - 204

JO - Trends in Microbiology

JF - Trends in Microbiology

IS - 5

ER -

Therapy for fungal diseases: Opportunities and priorities

Abstract

Access to Document

Other files and links

Fingerprint

Cite this